ICL Israel Chemicals is trading at $5.40 (4.9%) up in pre-market, extending its recent rebound following its Q2 2026 earnings report. - The company reported consolidated sales of $2.1 billion, up 17% year-over-year, and an operating income of $266 million, its best quarterly operating income performance in three years. - Shares are currently trading below the average analyst price target as the stock continues to recover from its recent downturn.